4.8 Article

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

期刊

NATURE GENETICS
卷 41, 期 11, 页码 1238-U105

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ng.465

关键词

-

资金

  1. Ruth L. Kirschstein NRSA
  2. KWF Kankerbestrijding
  3. US Department of Defense
  4. National Cancer Institute [K08CA134931, P50CA70907, R33CA128625, R01CA071606-12, P01CA098101-05, R01CA109038, P50CA90578]
  5. Genentech, Inc.
  6. Sara Thomas Monopoli Lung Cancer Research Fund
  7. Seaman Corporation Fund for Lung Cancer Research

向作者/读者索取更多资源

Lineage-survival oncogenes are activated by somatic DNA alterations in cancers arising from the cell lineages in which these genes play a role in normal development(1,2). Here we show that a peak of genomic amplification on chromosome 3q26.33 found in squamous cell carcinomas (SCCs) of the lung and esophagus contains the transcription factor gene SOX2, which is mutated in hereditary human esophageal malformations(3), is necessary for normal esophageal squamous development(4), promotes differentiation and proliferation of basal tracheal cells(5) and cooperates in induction of pluripotent stem cells(6-8). SOX2 expression is required for proliferation and anchorage-independent growth of lung and esophageal cell lines, as shown by RNA interference experiments. Furthermore, ectopic expression of SOX2 here cooperated with FOXE1 or FGFR2 to transform immortalized tracheobronchial epithelial cells. SOX2-driven tumors show expression of markers of both squamous differentiation and pluripotency. These characteristics identify SOX2 as a lineage-survival oncogene in lung and esophageal SCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据